DK0474712T3 - Anvendelse af lysolecitinderivater til fremstilling af et farmaceutisk præparat - Google Patents

Anvendelse af lysolecitinderivater til fremstilling af et farmaceutisk præparat

Info

Publication number
DK0474712T3
DK0474712T3 DK90908504.5T DK90908504T DK0474712T3 DK 0474712 T3 DK0474712 T3 DK 0474712T3 DK 90908504 T DK90908504 T DK 90908504T DK 0474712 T3 DK0474712 T3 DK 0474712T3
Authority
DK
Denmark
Prior art keywords
pct
pharmaceutical composition
preparation
carbon atoms
alkyl
Prior art date
Application number
DK90908504.5T
Other languages
Danish (da)
English (en)
Inventor
Manuel Modolell
Gerhard Munder
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK0474712T3 publication Critical patent/DK0474712T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK90908504.5T 1989-06-02 1990-05-31 Anvendelse af lysolecitinderivater til fremstilling af et farmaceutisk præparat DK0474712T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3918082A DE3918082A1 (de) 1989-06-02 1989-06-02 Mittel gegen autoimmunerkrankungen

Publications (1)

Publication Number Publication Date
DK0474712T3 true DK0474712T3 (da) 1993-11-29

Family

ID=6381972

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90908504.5T DK0474712T3 (da) 1989-06-02 1990-05-31 Anvendelse af lysolecitinderivater til fremstilling af et farmaceutisk præparat

Country Status (14)

Country Link
US (1) US5266564A (enExample)
EP (1) EP0474712B1 (enExample)
JP (1) JP2977894B2 (enExample)
AT (1) ATE94757T1 (enExample)
AU (1) AU5670690A (enExample)
CA (1) CA2056421C (enExample)
CS (1) CS276439B6 (enExample)
DE (2) DE3918082A1 (enExample)
DK (1) DK0474712T3 (enExample)
ES (1) ES2060173T3 (enExample)
GR (1) GR1001195B (enExample)
IE (1) IE64039B1 (enExample)
WO (1) WO1990014829A1 (enExample)
ZA (1) ZA904196B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3941009A1 (de) * 1989-12-12 1991-06-13 Medmark Pharma Gmbh Eliminierung von aktivierten lymphozyten
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US6583127B1 (en) 1998-12-21 2003-06-24 Inkeysa. Sa Use of etherlysophospholipids as antiinflammatory agents
SE9902155L (sv) * 1999-06-09 2000-12-10 Bjoern Rydevik Serum antibodies
JP2002228764A (ja) * 2001-02-02 2002-08-14 Fuji Photo Film Co Ltd 透光性シート体検出装置
WO2008055997A1 (en) * 2006-11-10 2008-05-15 Alphaptose Gmbh Use of tri-substituted glycerol compounds for the treatment of radiation injuries
JP5773569B2 (ja) 2006-11-10 2015-09-02 アルファプトーゼ ゲーエムベーハーAlphaptose Gnbh 受容体リガンド模倣体を検出する方法
DK2091520T3 (da) * 2006-11-10 2012-06-18 Alphaptose Gmbh Oral doseringsform omfattende trisubstituerede glycerol-forbindelser
EP2120873B1 (en) * 2006-12-20 2012-06-27 Alphaptose Gmbh Topical dosage form comprising tri-substituted glycerol compounds
PL2144618T5 (pl) * 2007-03-28 2025-07-21 Aker Biomarine Human Ingredients As Bio-skuteczne kompozycje oleju z kryla
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US20100226977A1 (en) * 2007-08-29 2010-09-09 Aker Biomarine Asa Low viscosity phospholipid compositions
US20090061067A1 (en) * 2007-08-29 2009-03-05 Aker Biomarine Asa Method for making krill meal
US8372812B2 (en) * 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
WO2013156630A1 (en) 2012-04-20 2013-10-24 Alphaptose Gmbh S-enantiomer of a tri-substituted glycerol compound
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
EP3256553A2 (en) 2015-02-11 2017-12-20 Aker Biomarine Antarctic AS Lipid compositions
WO2016128830A1 (en) 2015-02-11 2016-08-18 Aker Biomarine Antarctic As Lipid extraction processes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009343C3 (de) * 1970-02-27 1980-10-23 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Lysolecithinen als immunologische Adjuvantien
DE2009342C3 (de) * 1970-02-27 1980-12-18 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern
DE2619686C2 (de) * 1976-05-04 1986-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verwendung eines Lysolecithins zur Tumorbehandlung
CH670763A5 (enExample) * 1985-08-02 1989-07-14 Seuref Ag
DE3530767A1 (de) * 1985-08-28 1987-03-12 Max Planck Gesellschaft Mittel gegen multiple sklerose

Also Published As

Publication number Publication date
ZA904196B (en) 1991-03-27
CA2056421A1 (en) 1990-12-03
IE64039B1 (en) 1995-06-28
GR1001195B (el) 1993-06-07
EP0474712A1 (de) 1992-03-18
DE3918082A1 (de) 1991-01-24
US5266564A (en) 1993-11-30
ATE94757T1 (de) 1993-10-15
AU5670690A (en) 1991-01-07
DE59002863D1 (de) 1993-10-28
ES2060173T3 (es) 1994-11-16
IE901987L (en) 1990-12-02
CS276439B6 (en) 1992-05-13
GR900100406A (en) 1991-11-15
CS268990A3 (en) 1992-01-15
JPH04507096A (ja) 1992-12-10
EP0474712B1 (de) 1993-09-22
JP2977894B2 (ja) 1999-11-15
WO1990014829A1 (de) 1990-12-13
CA2056421C (en) 2000-10-10
DE3918082C2 (enExample) 1992-02-06

Similar Documents

Publication Publication Date Title
DE59002863D1 (de) Lysolecithinderivate zur behandlung von autoimmunerkrankungen.
DK160877C (da) Fremgangsmaade til fremstilling af 2-penemforbindelser
HUT51863A (enExample)
SE8700499D0 (sv) Novel pharmacologically active compounds
SE9002206D0 (sv) New compounds
DK0598770T3 (da) Pyrazinderivater samt fremstilling og anvendelse deraf
FI822543A0 (fi) Pyrrolidinderivat
AU601177B2 (en) Thiodiazolylurea-containing agent for defoliating plants
GB2243605A (en) Fluorinated 4"-cyano substituted terphenyls
EP0481299A3 (en) N-phenyl-piperidyl-4-amines and drugs containing them
FI913713A0 (fi) Nya bicykliska aminosubstituerade foereningar.
AU527523B2 (en) Hexahydro-1,4-oxazepines
FI873800A0 (fi) Nor-kolansyraderivat, foerfarande foer deras framstaellning, deras anvaendning samt farmaceutiska kompositioner innehaollande desamma.
ES2066756T3 (es) Nuevos derivados de tironina.
ATE69611T1 (de) Piperazinylalkylpiperazindion-derivate, ihre verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen.
SE8303721D0 (sv) Neue eburnan-oxim-ether-derivative und verfahren zur herstellung dieser verbindungen
DE69017146D1 (de) Verfahren zur Herstellung von 2-(3-Pyridyl)-Tetrahydrothiopyran-2-carbonsäurethioamid-1-(1R,2R)oxyden, die so erhaltenen 2-(3-Pyridyl)-Tetrahydrothiopyran-2-carbothioamid-1-(1R,2R)oxyde und diese enthaltende pharmazeutische Zusammenstellungen.
DK159649C (da) 4-hydroxy-alfa-benzhydrolderivater, fremgangsmaade til fremstilling deraf, farmaceutiske praeparater indeholdende disse, samt fremgangsmaade til fremstilling af disse farmaceutiske praeparater
ATE19472T1 (de) Verwendung von 5-phenyl-1,4-benzodoazepinen zur herstellung von analgetisch wirksamen pharmazeutischen zubereitungen.
ES2004215A6 (es) Procedimiento para preparar quinazolinas tetraciclicas
ATE36536T1 (de) Phosphoroimidate.
DE59204302D1 (de) 14Alpha,16alpha-Ethano- und 14alpha,16alpha-Ethenoestratriene.